Comparison of infection risks and clinical outcomes in patients with and without SARS-CoV-2 lung infection under renin-angiotensin-aldosterone system blockade: systematic review and meta-analysis
Aims Angiotensin-converting enzyme-2 (ACE2) is the receptor for SARS-CoV-2. Animal studies suggest that renin-angiotensin-aldosterone system (RAAS) blockers might increase the expression of ACE2 and potentially increase the risk of SARS-CoV-2 infection. Methods and Results The effect of ACE inhibito...
Gespeichert in:
| Hauptverfasser: | , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2021
|
| In: |
British journal of clinical pharmacology
Year: 2021, Jahrgang: 87, Heft: 6, Pages: 2475-2492 |
| ISSN: | 1365-2125 |
| DOI: | 10.1111/bcp.14660 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1111/bcp.14660 Verlag, kostenfrei, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1111/bcp.14660 
|
| Verfasserangaben: | Chang Chu, Shufei Zeng, Ahmed A. Hasan, Carl-Friedrich Hocher, Bernhard K. Krämer, Berthold Hocher |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1775662519 | ||
| 003 | DE-627 | ||
| 005 | 20230426125422.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 211028s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/bcp.14660 |2 doi | |
| 035 | |a (DE-627)1775662519 | ||
| 035 | |a (DE-599)KXP1775662519 | ||
| 035 | |a (OCoLC)1295678400 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Chu, Chang |d 1992- |e VerfasserIn |0 (DE-588)119616228X |0 (DE-627)1678018716 |4 aut | |
| 245 | 1 | 0 | |a Comparison of infection risks and clinical outcomes in patients with and without SARS-CoV-2 lung infection under renin-angiotensin-aldosterone system blockade |b systematic review and meta-analysis |c Chang Chu, Shufei Zeng, Ahmed A. Hasan, Carl-Friedrich Hocher, Bernhard K. Krämer, Berthold Hocher |
| 264 | 1 | |c 2021 | |
| 300 | |a 18 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a First published: 20 November 2020 | ||
| 500 | |a Gesehen am 28.10.2021 | ||
| 520 | |a Aims Angiotensin-converting enzyme-2 (ACE2) is the receptor for SARS-CoV-2. Animal studies suggest that renin-angiotensin-aldosterone system (RAAS) blockers might increase the expression of ACE2 and potentially increase the risk of SARS-CoV-2 infection. Methods and Results The effect of ACE inhibitor (ACEI) treatment on the pneumonia incidence in non-COVID-19 patients (25 studies, 330 780 patients) was associated with a 26% reduction of pneumonia risk (odds ratio [OR]: 0.74, P < .001). Pneumonia-related death cases in ACEI-treated non-COVID-19 patients were reduced by 27% (OR: 0.73, P = .004). However, angiotensin II receptor blockers (ARB) treatment (10 studies, 275 621 non-COVID-19 patients) did not alter pneumonia risk in patients. Pneumonia-related death cases in ARB-treated non-COVID-19 patients was analysed only in 1 study and was significantly reduced (OR, 0.47; 95% confidence interval, 0.30 to 0.72). Results from 11 studies (8.4 million patients) showed that the risk of getting infected with the SARS-CoV-2 virus was reduced by 13% (OR: 0.87, P = .014) in patients treated with ACEI, whereas analysis from 10 studies (8.4 million patients) treated with ARBs showed no effect (OR, 0.92, P = .354). Results from 34 studies in 67 644 COVID-19 patients showed that RAAS blockade reduces all-cause mortality by 24% (OR = 0.76, P = .04). Conclusion ACEIs reduce the risk of getting infected with the SARS-CoV-2 virus. Blocking the RAAS may decrease all-cause mortality in COVID-19 patients. ACEIs also reduce the risk of non-COVID pneumonia. All-cause mortality due to non-COVID pneumonia is reduced by ACEI and potentially by ARBs. | ||
| 650 | 4 | |a ACE inhibitors | |
| 650 | 4 | |a ACE2 | |
| 650 | 4 | |a angiotensin II receptor blockers | |
| 650 | 4 | |a SARS-CoV-2 | |
| 700 | 1 | |a Zeng, Shufei |e VerfasserIn |0 (DE-588)1227728301 |0 (DE-627)174866980X |4 aut | |
| 700 | 1 | |a Hasan, Ahmed A. |e VerfasserIn |0 (DE-588)1172932042 |0 (DE-627)1042013187 |0 (DE-576)514901853 |4 aut | |
| 700 | 1 | |a Hocher, Carl-Friedrich |e VerfasserIn |0 (DE-588)1281436399 |0 (DE-627)1837066191 |4 aut | |
| 700 | 1 | |a Krämer, Bernhard |d 1957- |e VerfasserIn |0 (DE-588)14017589X |0 (DE-627)70358927X |0 (DE-576)314926852 |4 aut | |
| 700 | 1 | |a Hocher, Berthold |d 1962- |e VerfasserIn |0 (DE-588)12000397X |0 (DE-627)696292173 |0 (DE-576)291991033 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t British journal of clinical pharmacology |d Oxford : Wiley-Blackwell, 1974 |g 87(2021), 6, Seite 2475-2492 |h Online-Ressource |w (DE-627)306585995 |w (DE-600)1498142-7 |w (DE-576)091140056 |x 1365-2125 |7 nnas |a Comparison of infection risks and clinical outcomes in patients with and without SARS-CoV-2 lung infection under renin-angiotensin-aldosterone system blockade systematic review and meta-analysis |
| 773 | 1 | 8 | |g volume:87 |g year:2021 |g number:6 |g pages:2475-2492 |g extent:18 |a Comparison of infection risks and clinical outcomes in patients with and without SARS-CoV-2 lung infection under renin-angiotensin-aldosterone system blockade systematic review and meta-analysis |
| 856 | 4 | 0 | |u https://doi.org/10.1111/bcp.14660 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://onlinelibrary.wiley.com/doi/abs/10.1111/bcp.14660 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20230220 | ||
| 993 | |a Article | ||
| 994 | |a 2021 | ||
| 998 | |g 12000397X |a Hocher, Berthold |m 12000397X:Hocher, Berthold |d 60000 |d 61400 |e 60000PH12000397X |e 61400PH12000397X |k 0/60000/ |k 1/60000/61400/ |p 6 |y j | ||
| 998 | |g 14017589X |a Krämer, Bernhard |m 14017589X:Krämer, Bernhard |d 60000 |d 61400 |e 60000PK14017589X |e 61400PK14017589X |k 0/60000/ |k 1/60000/61400/ |p 5 | ||
| 998 | |g 1281436399 |a Hocher, Carl-Friedrich |m 1281436399:Hocher, Carl-Friedrich |d 60000 |e 60000PH1281436399 |k 0/60000/ |p 4 | ||
| 998 | |g 119616228X |a Chu, Chang |m 119616228X:Chu, Chang |p 1 |x j | ||
| 999 | |a KXP-PPN1775662519 |e 4274795489 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"given":"Chang","role":"aut","family":"Chu","display":"Chu, Chang"},{"display":"Zeng, Shufei","family":"Zeng","role":"aut","given":"Shufei"},{"given":"Ahmed A.","role":"aut","family":"Hasan","display":"Hasan, Ahmed A."},{"display":"Hocher, Carl-Friedrich","family":"Hocher","role":"aut","given":"Carl-Friedrich"},{"display":"Krämer, Bernhard","family":"Krämer","given":"Bernhard","role":"aut"},{"role":"aut","given":"Berthold","family":"Hocher","display":"Hocher, Berthold"}],"note":["First published: 20 November 2020","Gesehen am 28.10.2021"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"origin":[{"dateIssuedDisp":"2021","dateIssuedKey":"2021"}],"title":[{"title_sort":"Comparison of infection risks and clinical outcomes in patients with and without SARS-CoV-2 lung infection under renin-angiotensin-aldosterone system blockade","subtitle":"systematic review and meta-analysis","title":"Comparison of infection risks and clinical outcomes in patients with and without SARS-CoV-2 lung infection under renin-angiotensin-aldosterone system blockade"}],"language":["eng"],"physDesc":[{"extent":"18 S."}],"name":{"displayForm":["Chang Chu, Shufei Zeng, Ahmed A. Hasan, Carl-Friedrich Hocher, Bernhard K. Krämer, Berthold Hocher"]},"recId":"1775662519","id":{"doi":["10.1111/bcp.14660"],"eki":["1775662519"]},"relHost":[{"disp":"Comparison of infection risks and clinical outcomes in patients with and without SARS-CoV-2 lung infection under renin-angiotensin-aldosterone system blockade systematic review and meta-analysisBritish journal of clinical pharmacology","part":{"issue":"6","year":"2021","text":"87(2021), 6, Seite 2475-2492","pages":"2475-2492","extent":"18","volume":"87"},"origin":[{"publisherPlace":"Oxford ; Oxford ; Oxford [u.a.]","dateIssuedDisp":"1974-","publisher":"Wiley-Blackwell ; Blackwell Science ; Blackwell","dateIssuedKey":"1974"}],"note":["Gesehen am 20.03.2014"],"type":{"media":"Online-Ressource","bibl":"periodical"},"titleAlt":[{"title":"BJCP"}],"title":[{"subtitle":"BJCP","title_sort":"British journal of clinical pharmacology","title":"British journal of clinical pharmacology"}],"language":["eng"],"physDesc":[{"extent":"Online-Ressource"}],"recId":"306585995","pubHistory":["1.1974 -"],"id":{"zdb":["1498142-7"],"eki":["306585995"],"issn":["1365-2125"],"doi":["10.1111/(ISSN)1365-2125"]}}]} | ||
| SRT | |a CHUCHANGZECOMPARISON2021 | ||